(Updated)

GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of 24.80p, better than the analyst estimate of 24.50p. Revenue for the quarter came in at GBP8.9 billion versus the consensus estimate of GBP9.02 billion.

2020 guidance

• Expect Adjusted EPS to decline -1% to -4% CER
• Expect 80p dividend for 2020

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.